Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

A team from Nanjing Leads Biolabs Co. Ltd. presented the discovery and preclinical characterization of LBL-042, a novel bispecific antibody designed to simultaneously target PD-1 and LILRB1/2, with ...

Nectin-4 antibody-drug conjugate (ADC) and checkpoint inhibitor combinations have represented a great advancement in the treatment of bladder cancer, but relapse and treatment-related toxicities ...

Researchers have developed a unique type of antibody that both targets and delivers a drug package via the antibody itself, while simultaneously activating the immune system (“3-in-1 design”) for ...

(Shutterstock) Researchers have developed a unique type of antibody that both targets and delivers a drug package via the ...

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); ...

Transaction valued at €3.5 millionThe partners have enjoyed a successful discovery collaboration since 2021LUND, SWEDEN / ACCESSWIRE / November 19, 2024 / Alligator Bioscience (STO:ATORX) today announ ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and ...

Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and ...

Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and ...